Skip to Main Content

Paper Details

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.
Nat Biotechnol
405
2014
CTC, CTCs, cancer, cancer genomes, circulating tumor cells, exome, exomes, matched tissue, metastatic prostate cancer, patients, primary tumor, prostate cancer, rare cells, tumor
Author NameAffiliation
Jens G Lohr1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School
Kristian Cibulskis1] The Eli and Edythe L. Broad Institute of MIT and Harvard
Mara RosenbergThe Eli and Edythe L. Broad Institute of MIT and Harvard
Mara RosenbergThe Eli and Edythe L. Broad Institute of MIT and Harvard
Joshua M Francis1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute
Alex K ShalekHarvard University
Alex K ShalekHarvard University
Rahul SatijaThe Eli and Edythe L. Broad Institute of MIT and Harvard
Rahul SatijaThe Eli and Edythe L. Broad Institute of MIT and Harvard
Brendan BlumenstielThe Eli and Edythe L. Broad Institute of MIT and Harvard
Brendan BlumenstielThe Eli and Edythe L. Broad Institute of MIT and Harvard
Carrie SougnezThe Eli and Edythe L. Broad Institute of MIT and Harvard
Carrie SougnezThe Eli and Edythe L. Broad Institute of MIT and Harvard
Bang WongThe Eli and Edythe L. Broad Institute of MIT and Harvard
Daniel AuclairThe Eli and Edythe L. Broad Institute of MIT and Harvard
Eliezer M Van Allen1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School
Eliezer M Van Allen1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School
Rosina T LisDana-Farber Cancer Institute
Mary-Ellen Taplin1] Dana-Farber Cancer Institute, USA. [2] Harvard Medical School
Massimo Loda1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School, USA. [4] Brigham and Women's Hospital
Aviv Regev1] The Eli and Edythe L. Broad Institute of MIT and Harvard, Massachusetts Institute of Technology, USA. [3] Howard Hughes Medical Institute
Aviv Regev1] The Eli and Edythe L. Broad Institute of MIT and Harvard, Massachusetts Institute of Technology, USA. [3] Howard Hughes Medical Institute
Matthew Meyerson1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School
Matthew Meyerson1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School
William C Hahn1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School, USA. [4] Brigham and Women's Hospital
William C Hahn1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School, USA. [4] Brigham and Women's Hospital
Philip W Kantoff1] Dana-Farber Cancer Institute, USA. [2] Harvard Medical School
Philip W Kantoff1] Dana-Farber Cancer Institute, USA. [2] Harvard Medical School
Todd R Golub1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School, USA. [4] Howard Hughes Medical Institute
Todd R Golub1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Dana-Farber Cancer Institute, USA. [3] Harvard Medical School, USA. [4] Howard Hughes Medical Institute
Gad Getz1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Massachusetts General Hospital
Gad Getz1] The Eli and Edythe L. Broad Institute of MIT and Harvard, USA. [2] Massachusetts General Hospital
Jesse S BoehmThe Eli and Edythe L. Broad Institute of MIT and Harvard
Jesse S BoehmThe Eli and Edythe L. Broad Institute of MIT and Harvard
  • 1 - 34

Datasets